Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas

Journal of Clinical Investigation

Volumn 117, Issue 4, 2007, Pages 1019-1028

  Sarek, Grzegorz ^a   Kurki, Sari ^a,b   Enbäck, Juulia ^a   Iotzova, Guergana ^c,d   Haas, Juergen ^c,d   Laakkonen, Pirjo ^a   Laiho, Marikki ^a,b   Ojala, Päivi M ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LATENCY ASSOCIATED NUCLEAR ANTIGEN; NUTLIN 3A; PROTEIN INHIBITOR; PROTEIN MDM2; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL KILLING; COMPLEX FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; HUMAN; HUMAN CELL; HUMAN HERPESVIRUS 8; MOUSE; NONHUMAN; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TUMOR REGRESSION;

EID: 34147158893     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI30945     Document Type: Article

References (52)

1. Chang, Y., et al. 1994. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science. 266:1865-1869.
2. Soulier, J., et al. 1995. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood. 86:1276-1280.
3. Cesarman, E., et al. 1995. In vitro establishment and characterization of two acquired immunodeficiency syndrome-related lymphoma cell lines (BC-1 and BC-2) containing Kaposi's sarcoma-associated herpesvirus-like (KSHV) DNA sequences. Blood. 86:2708-2714.
4. Ablashi, D.V., Chatlynne, L.G., Whitman, J.E., Jr., and Cesarman, E. 2002. Spectrum of Kaposi's sarcoma-associated herpesvirus, or human herpesvirus 8, diseases. Clin. Microbiol. Rev. 15:439-464.
5. Cesarman, E., and Knowles, D.M. 1999. The role of Kaposi's sarcoma-associated herpesvirus (KSHV/ HHV-8) in lymphoproliferative diseases. Semin. Cancer Biol. 9:165-174.
6. Carbone, A., and Gloghini, A. 2005. AIDS-related lymphomas: from pathogenesis to pathology. Br. J. Haematol. 130:662-670.
7. Jarviluoma, A., and Ojala, P.M. 2006. Cell signaling pathways engaged by KSHV. Biochim. Biophys. Acta. 1766:140-158.
8. Vogelstein, B., Lane, D., and Levine, A.J. 2000. Surfing the p53 network. Nature. 408:307-310.
9. Harris, S.L., and Levine, A.J. 2005. The p53 pathway: positive and negative feedback loops. Oncogene. 24:2899-2908.
10. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C.C. 1991. p53 mutations in human cancers. Science. 253:49-53.
11. Hermeking, H., and Eick, D. 1994. Mediation of c-Myc-induced apoptosis by p53. Science. 265:2091-2093.
12. Attardi, L.D., Lowe, S.W., Brugarolas, J., and Jacks, T. 1996. Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene-mediated apoptosis. EMBO J. 15:3693-3701.
13. Schmitt, C.A., et al. 2002. Dissecting p53 tumor suppressor functions in vivo. Cancer Cell. 1:289-298.
14. Honda, R., Tanaka, H., and Yasuda, H. 1997. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420:25-27.
15. Vassilev, L.T., et al. 2004. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 303:844-848.
16. Tovar, C., et al. 2006. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc. Natl. Acad. Sci. U. S. A. 103:1888-1893.
17. Boulanger, E., et al. 2005. Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS. J. Clin. Oncol. 23:4372-4380.
18. Keller, S.A., et al. 2006. NF-kappaB is essential for the progression of KSHV- and EBV-infected lymphomas in vivo. Blood. 107:3295-3302.
19. Ghosh, S.K., et al. 2003. Potentiation of TRAIL-induced apoptosis in primary effusion lymphoma through azidothymidine-mediated inhibition of NF-kappa B. Blood. 101:2321-2327.
20. Godfrey, A., Anderson, J., Papanastasiou, A., Takeuchi, Y., and Boshoff, C. 2005. Inhibiting primary effusion lymphoma by lentiviral vectors encoding short hairpin RNA. Blood. 105:2510-2518.
21. Aoki, Y., and Tosato, G. 2004. Therapeutic options for human herpesvirus-8/Kaposi's sarcoma-associated herpesvirus-related disorders. Expert Rev. Anti Infect. Ther. 2:213-225.
22. Simonelli, C., et al. 2003. Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study. J. Clin. Oncol. 21:3948-3954.
23. Nador, R.G., et al. 1996. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood. 88:645-656.
24. Carbone, A., et al. 1998. Establishment and characterization of EBV-positive and EBV-negative primary effusion lymphoma cell lines harbouring human herpesvirus type-8. Br. J. Haematol. 102:1081-1089.
25. Katano, H., Sato, Y., and Sata, T. 2001. Expression of p53 and human herpesvirus-8 (HHV-8)-encoded latency-associated nuclear antigen with inhibition of apoptosis in HHV-8-associated malignancies. Cancer. 92:3076-3084.
26. Friborg, J., Jr., Kong, W., Hottiger, M.O., and Nabel, G.J. 1999. p53 inhibition by the LANA protein of KSHV protects against cell death. Nature. 402:889-894.
27. Brummelkamp, T.R., et al. 2006. An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors. Nat. Chem. Biol. 2:202-206.
28. Cai, Q.L., Knight, J.S., Verma, S.C., Zald, P., and Robertson, E.S. 2006. EC5S ubiquitin complex is recruited by KSHV latent antigen LANA for degradation of the VHL and p53 tumor suppressors. PLoS Pathog. 2:e116.
29. Sin, S.H., et al. 2006. Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling. Blood. 109:2165-2173.
30. Wang, B., Matsuoka, S., Carpenter, P.B., and Elledge, S.J. 2002. 53BP1, a mediator of the DNA damage checkpoint. Science. 298:1435-1438.
31. Abraham, R.T. 2002. Checkpoint signalling: focusing on 53BP1. Nat. Cell Biol. 4:E277-E279.
32. Waldman, T., Kinzler, K.W., and Vogelstein, B. 1995. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res. 55:5187-5190.
33. Kojima, K., et al. 2005. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood. 106:3150-3159.
34. Stuhmer, T., et al. 2005. Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood. 106:3609-3617.
35. Coll-Mulet, L., et al. 2006. MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood. 107:4109-4114.
36. Secchiero, P., et al. 2006. Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). Blood. 107:4122-4129.
37. Edgell, C.J., McDonald, C.C., and Graham, J.B. 1983. Permanent cell line expressing human factor VIII-related antigen established by hybridization. Proc. Natl. Acad. Sci. U. S. A. 80:3734-3737.
38. Vieira, J., and O'Hearn, P.M. 2004. Use of the red fluorescent protein as a marker of Kaposi's sarcoma-associated herpesvirus lytic gene expression. Virology. 325:225-240.
39. DiTullio, R.A., Jr., et al. 2002. 53BP1 functions in an ATM-dependent checkpoint pathway that is constitutively activated in human cancer. Nat. Cell Biol. 4:998-1002.
40. Gorgoulis, V.G., et al. 2005. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature. 434:907-913.
41. Staudt, M.R., et al. 2004. The tumor microenvironment controls primary effusion lymphoma growth in vivo. Cancer Res. 64:4790-4799.
42. Petre, C.E., Sin, S.H., and Dittmer, D.P. 2007. Functional p53 signaling in Kaposi's sarcoma-associated herpesvirus (KSHV) lymphomas-implications for therapy. J. Virol. 81:1912-1922.
43. Inman, G.J., and Farrell, P.J. 1995. Epstein-Barr virus EBNA-LP and transcription regulation properties of pRB, p107 and p53 in transfection assays. J. Gen. Virol. 76:2141-2149.
44. Pokrovskaja, K., Mattsson, K., Kashuba, E., Klein, G., and Szekely, L. 2001. Proteasome inhibitor induces nucleolar translocation of Epstein-Barr virus-encoded EBNA-5. J. Gen. Virol. 82:345-358.
45. Kashuba, E., et al. 2003. EBV-encoded EBNA-5 associates with P14ARF in extranucleolar inclusions and prolongs the survival of P14ARF-expressing cells. Int. J. Cancer. 105:644-653.
46. Bartkova, J., et al. 2005. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 434:864-870.
47. Boulanger, E., Daniel, M.T., Agbalika, F., and Oksenhendler, E. 2003. Combined chemotherapy including high-dose methotrexate in KSHV/ HHV8-associated primary effusion lymphoma. Am. J. Hematol. 73:143-148.
48. Arvanitakis, L., et al. 1996. Establishment and characterization of a primary effusion (body cavity-based) lymphoma cell line (BC-3) harboring kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in the absence of Epstein-Barr virus. Blood. 88:2648-2654.
49. Renne, R., et al. 1996. Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture. Nat. Med. 2:342-346.
50. Rieber, A.J., Marr, H.S., Comer, M.B., and Edgell, C.J. 1993. Extent of differentiated gene expression in the human endothelium-derived EA.hy926 cell line. Thromb. Haemost. 69:476-480.
51. Sarek, G., Jarviluoma, A., and Ojala, P.M. 2006. KSHV viral cyclin inactivates p27KIP1 through Ser10 and Thr187 phosphorylation in proliferating primary effusion lymphomas. Blood. 107:725-732.
52. Schueneman, A.J., et al. 2003. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res. 63:4009-4016.